98%
921
2 minutes
20
IntroductionEnd-of-life care for liver transplant recipients is often characterized by high utilization of invasive procedures, prolonged hospital stays, and elevated health care costs. Despite evidence demonstrating that palliative care can reduce aggressive interventions, improve patient-centered outcomes, and lower costs, its integration into transplant care remains inconsistent.MethodsA retrospective analysis was conducted using the National Inpatient Sample database (2016-2021). Hospitalizations ending in death for liver transplant recipients were compared to non-recipients regarding invasive procedures, health care costs, and the impact of palliative care consultations. Assessed procedures included: mechanical ventilation, tracheostomy, enteral and parenteral nutrition support, red blood cell transfusion, renal replacement therapy, central line placement, and cardiopulmonary resuscitation. Multivariable regression models adjusted for demographic and clinical covariates were utilized.ResultsAmong 4,582,658 terminal hospitalizations, liver transplant recipients (n = 5995) were younger (mean age: 66.0 vs 70.9 years, < 0.001), had higher comorbidity burdens, and were more likely to have undergone one or more of the assessed procedures (74.7% vs 58.4%, < .001) compared to non-recipients. Hospitalization costs were increased in transplant recipients ($62,630 vs $46,930, < .001). Palliative care consultations were associated with reduced procedure utilization (69.9% vs 83.7%, < .001), shorter hospital stays, and lower costs ($46,930 vs $62,630, < .001).DiscussionLiver transplant recipients face unique end-of-life care challenges, including greater reliance on high-intensity interventions and associated costs. Palliative care is associated with less invasive procedures and lower costs, highlighting the need for its integration into transplant care pathways.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10499091251340685 | DOI Listing |
Clin Transplant Res
September 2025
Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea.
Background: Calcineurin inhibitor (CNI) toxicity is a significant cause of graft dysfunction in kidney transplant recipients, yet distinguishing it from acute rejection (AR) and acute tubular necrosis (ATN) remains challenging. This study investigated the use of urinary mRNA biomarkers as a noninvasive tool for identifying CNI toxicity.
Methods: We retrospectively enrolled 110 kidney transplant recipients and classified them into four groups based on pathological findings: stable graft function (n=35), CNI toxicity (n=25), AR (n=30), and ATN (n=20).
Eur J Immunol
September 2025
CHU Nantes, Nantes Université, INSERM, Centre de Recherche Translationnelle En Transplantation et Immunologie (CR2TI), Nantes, France.
In the field of lung transplantation (LTx), the survival of lung transplant recipients (LTRs) is limited by events such as primary graft dysfunction (PGD), infections, and acute rejection (AR), which promote the development of chronic lung allograft dysfunction (CLAD). Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as key players in LTx because of their roles in immune regulation, inflammation, and antigen presentation. EVs carry immunologically active molecules such as MHC class I/II proteins, cytokines, and lung self-antigens (SAgs), suggesting their involvement in infections and both AR and CLAD.
View Article and Find Full Text PDFTransplantation
September 2025
General Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Background: Mortality after liver transplantation (LT) for hepatocellular carcinoma (HCC) is mainly driven by HCC recurrence. We sought to determine whether post-recurrence survival (PRS) has improved during the last 2 decades.
Methods: Using the Scientific Registry of Transplant Recipients, we included all patients who underwent LT for HCC between 2003 and 2020 and experienced HCC recurrence.
Transplant Cell Ther
September 2025
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine); Hangzhou, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University; Hangzhou, China. Electronic address: szyyblood@1
Aplastic anemia (AA) is a bone marrow failure disorder treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite improvements in conditioning regimens and GVHD prophylaxis, graft failure and GVHD remain critical challenges. This study compared the efficacy of mesenchymal stem cells (MSCs) and umbilical cord blood cells (UCBs) as adjunctive therapies in 184 AA patients undergoing allo-HSCT.
View Article and Find Full Text PDFAm J Transplant
September 2025
Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France. Electronic address:
A comprehensive analysis was performed on all consecutive biopsy-proven Thrombotic Microangiopathy (TMA) complicating kidney transplantation in the post C5 inhibitor era (from 2009) to identify pathological profiles, determine causes and establish risk factor associated with death-censored graft survival, in two French center. Pathological criteria were assessed according to the TMA Banff Working Group, followed by an unbiased analysis to identify distinct subgroups. 119 cases were identified, 8(6.
View Article and Find Full Text PDF